The prognostic impact of c-KIT mutation in systemic mastocytosis associated with acute myeloid leukaemia patients

Leukemia Research

Volumn 37, Issue 8, 2013, Pages 883-888

  Won, Dahae ^a   Chi, Hyun Sook ^a   Shim, Hyoeun ^a   Jang, Seongsoo ^a   Park, Chan Jeoung ^a   Lee, Je Hwan ^a  

^a University of Ulsan College of Medicine   (South Korea)

Author keywords

Acute myeloid leukaemia; C KIT; Prognosis; RUNX1 RUNX1T1; Systemic mastocytosis

Indexed keywords

CD2 ANTIGEN; CYTARABINE; DAUNORUBICIN; IDARUBICIN; INTERLEUKIN 2 RECEPTOR ALPHA; STEM CELL FACTOR RECEPTOR; TOLONIUM CHLORIDE; TRANSCRIPTION FACTOR RUNX1; TRYPTASE;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIGEN EXPRESSION; ARTICLE; AUTOLOGOUS BONE MARROW TRANSPLANTATION; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER REGRESSION; CELL INFILTRATION; CHILD; CHROMOSOME 5Q; CHROMOSOME 8Q; CHROMOSOME TRANSLOCATION 5; CHROMOSOME TRANSLOCATION 8; CLINICAL ARTICLE; CONTINUOUS INFUSION; CYTOCHEMISTRY; DISEASE ASSOCIATION; FEMALE; FUSION GENE; GENE MUTATION; HUMAN; IMMUNOHISTOCHEMISTRY; MALE; MAST CELL; MUTATIONAL ANALYSIS; ONCOGENE C KIT; OVERALL SURVIVAL; PRESCHOOL CHILD; PRIORITY JOURNAL; RUNX1 RUNX1T1 GENE; SCHOOL CHILD; SYSTEMIC MASTOCYTOSIS;

EID: 84879780591     PISSN: 01452126     EISSN: 18735835     Source Type: Journal    
DOI: 10.1016/j.leukres.2013.04.020     Document Type: Article

References (34)

1. Boissel N., Leroy H., Brethon B., et al. Incidence and prognostic impact of c-Kit, FLT3, and Ras gene mutations in core binding factor acute myeloid leukemia (CBF-AML). Leukemia 2006, 20(6):965-970.
2. Rollig C., Bornhauser M., Thiede C., et al. Long-term prognosis of acute myeloid leukemia according to the new genetic risk classification of the European LeukemiaNet Recommendations: evaluation of the proposed reporting system. J Clin Oncol 2011.
3. Foran J.M. New prognostic markers in acute myeloid leukemia: perspective from the clinic. Hematol Am Soc Hematol Educ Program 2010, 2010:47-55.
4. Park S.H., Chi H.S., Min S.K., et al. Prognostic impact of c-KIT mutations in core binding factor acute myeloid leukemia. Leuk Res 2011.
5. Horny H-P.M.D., Bennett J.M., Bain B.J., et al. Mastocytosis. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 54-63. International Agency for Research on Cancer, Geneva. 2nd ed. S.H. Swerdlow, N.L. Harris, E.S. Jaffe, S.A. Pileri, H. Stein, J. Thiele (Eds.).
6. Pullarkat S.T., Pullarkat V., Kroft S.H., et al. Systemic mastocytosis associated with t(8;21)(q22;q22) acute myeloid leukemia. J Hematop 2009, 2(1):27-33.
7. Valent P., Horny H.P., Escribano L., et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res 2001, 25(7):603-625.
8. Sanchez-Munoz L., Alvarez-Twose I., Garcia-Montero A.C., et al. Evaluation of the WHO criteria for the classification of patients with mastocytosis. Mod Pathol 2011.
9. Horny H.P., Sotlar K., Sperr W.R., et al. Systemic mastocytosis with associated clonal haematological non-mast cell lineage diseases: a histopathological challenge. J Clin Pathol 2004, 57(6):604-608.
10. Travis W.D., Li C.Y., Yam L.T., et al. Significance of systemic mast cell disease with associated hematologic disorders. Cancer 1988, 62(5):965-972.
11. Brunning R.D., McKenna R.W., Rosai J., et al. Systemic mastocytosis. Extracutaneous manifestations. Am J Surg Pathol 1983, 7(5):425-438.
12. Gleixner K.V., Mayerhofer M., Cerny-Reiterer S., et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk-activation and disruption by dasatinib and bosutinib. Blood 2011.
13. Wilson T.M., Maric I., Simakova O., et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica 2011, 96(3):459-463.
14. Kristensen T., Vestergaard H., Moller M.B. Improved detection of the KIT D816V mutation in patients with systemic mastocytosis using a quantitative and highly sensitive real-time qPCR assay. J Mol Diagn 2011, 13(2):180-188.
15. Sotlar K., Fridrich C., Mall A., et al. Detection of c-kit point mutation Asp-816→Val in microdissected pooled single mast cells and leukemic cells in a patient with systemic mastocytosis and concomitant chronic myelomonocytic leukemia. Leuk Res 2002, 26(11):979-984.
16. Sperr W.R., Walchshofer S., Horny H.P., et al. Systemic mastocytosis associated with acute myeloid leukaemia: report of two cases and detection of the c-kit mutation Asp-816 to Val. Br J Haematol 1998, 103(3):740-749.
17. Pullarkat V.A., Bueso-Ramos C., Lai R., et al. Systemic mastocytosis with associated clonal hematological non-mast-cell lineage disease: analysis of clinicopathologic features and activating c-kit mutations. Am J Hematol 2003, 73(1):12-17.
18. Sotlar K., Colak S., Bache A., et al. Variable presence of KITD816V in clonal haematological non-mast cell lineage diseases associated with systemic mastocytosis (SM-AHNMD). J Pathol 2010, 220(5):586-595.
19. Cho Y.U., Chi H.S., Park C.J., et al. Rapid detection of prognostically significant fusion transcripts in acute leukemia using simplified multiplex reverse transcription polymerase chain reaction. J Korean Med Sci 2012, 27(10):1155-1161.
20. Sarriera J.E., Albitar M., Estrov Z., et al. Comparison of outcome in acute myelogenous leukemia patients with translocation (8;21) found by standard cytogenetic analysis and patients with AML1/ETO fusion transcript found only by PCR testing. Leukemia 2001, 15(1):57-61.
21. Miettinen M., Majidi M., Lasota J. Pathology and diagnostic criteria of gastrointestinal stromal tumors (GISTs): a review. Eur J Cancer 2002, 38(Suppl 5):S39-S51.
22. Tian Q., Frierson H.F., Krystal G.W., et al. Activating c-kit gene mutations in human germ cell tumors. Am J Pathol 1999, 154(6):1643-1647.
23. Cairoli R., Beghini A., Grillo G., et al. Prognostic impact of c-KIT mutations in core binding factor leukemias: an Italian retrospective study. Blood 2006, 107(9):3463-3468.
24. Schnittger S., Kohl T.M., Haferlach T., et al. KIT-D816 mutations in AML1-ETO-positive AML are associated with impaired event-free and overall survival. Blood 2006, 107(5):1791-1799.
25. Shimada A., Taki T., Tabuchi K., et al. KIT mutations, and not FLT3 internal tandem duplication, are strongly associated with a poor prognosis in pediatric acute myeloid leukemia with t(8;21): a study of the Japanese Childhood AML Cooperative Study Group. Blood 2006, 107(5):1806-1809.
26. Amon U., Hartmann K., Horny H.P., et al. Mastocytosis - an update. J Dtsch Dermatol Ges 2010, 8(9):695-711. [quiz 2].
27. Kristensen T., Preiss B., Broesby-Olsen S., et al. Systemic mastocytosis is uncommon in KIT D816V mutation positive core-binding factor acute myeloid leukemia. Leuk Lymphoma 2012, 53(7):1338-1344.
28. Garcia-Montero A.C., Jara-Acevedo M., Teodosio C., et al. KIT mutation in mast cells and other bone marrow hematopoietic cell lineages in systemic mast cell disorders: a prospective study of the Spanish Network on Mastocytosis (REMA) in a series of 113 patients. Blood 2006, 108(7):2366-2372.
29. Sperr W.R., Jordan J.H., Baghestanian M., et al. Expression of mast cell tryptase by myeloblasts in a group of patients with acute myeloid leukemia. Blood 2001, 98(7):2200-2209.
30. Nagai S., Ichikawa M., Takahashi T., et al. The origin of neoplastic mast cells in systemic mastocytosis with AML1/ETO-positive acute myeloid leukemia. Exp Hematol 2007, 35(11):1747-1752.
31. Pullarkat V., Bedell V., Kim Y., et al. Neoplastic mast cells in systemic mastocytosis associated with t(8;21) acute myeloid leukemia are derived from the leukemic clone. Leuk Res 2007, 31(2):261-265.
32. Fritsche-Polanz R., Fritz M., Huber A., et al. High frequency of concomitant mastocytosis in patients with acute myeloid leukemia exhibiting the transforming KIT mutation D816V. Mol Oncol 2010, 4(4):335-346.
33. Bernd H.W., Sotlar K., Lorenzen J., et al. Acute myeloid leukaemia with t(8;21) associated with occult mastocytosis. Report of an unusual case and review of the literature. J Clin Pathol 2004, 57(3):324-328.
34. Parker R.I. Hematologic aspects of systemic mastocytosis. Hematol Oncol Clin North Am 2000, 14(3):557-568.